Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation
Fei Sun(University of California, Los Angeles), Min Shi(Nanfang Hospital), Zhiqi Yao(Nanfang Hospital), Wangjun Liao(Sun Yat-sen University), Yujing Tan(Guangdong University of Technology), Jing Wu(Sun Yat-sen University), Qiong Huang(Central South University), Xiaoxiang Rong(Nanfang Hospital), Qijing Wu(Nanfang Hospital), Fangzhen Yao(Nanfang Hospital), Chunhui Gu(Nanfang Hospital), Yulu Shi(Nanfang Hospital), Yawen Wang(North China University of Technology), Yong Li(Baylor College of Medicine), Jiao Wang(Nanfang Hospital), Yang Zhao(The University of Texas MD Anderson Cancer Center), Chunlin Wang(Stanford University), Shaowei Li(Xiamen University), Yu Jiang(Nanfang Hospital), Jianjun Peng(Hunan University of Science and Technology), Na Huang(Nanfang Hospital), Bishan Liang(Nanfang Hospital), Chunting Zeng(Nanfang Hospital)
Cited by 13
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Circular RNAs function as ceRNAs to regulate and control human cancer progression
|Molecular Cancer|2018|1.1k
Neoantigen vaccine: an emerging tumor immunotherapy
|Molecular Cancer|2019|718
Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA
|Molecular Cancer|2020|578